摘要
目的探讨心脉隆注射液对老年慢性心力衰竭合并缓慢心律失常的临床疗效及对患者血肌酐(SCr)、尿素氮(BUN)、N末端B型脑钠肽前体(NT-proBNP)的影响。方法选取医院2014年1月至2017年1月收治的老年慢性心力衰竭合并缓慢心律失常患者112例,随机分为对照组和观察组,各56例。两组患者均给予原发病基础治疗和常规治疗,观察组患者静脉滴注心脉隆注射液,对照组患者维持泵入多巴酚丁胺,均治疗10 d。结果观察组总有效率为92.86%,显著高于对照组的64.29%(P<0.05);治疗后,观察组患者NT-proBNP,SCr,BUN水平较治疗前和对照组明显降低(P<0.05),左室射血分数(LVEF)、心率、24 h尿量均较治疗前和对照组明显提高(P<0.05);观察组在治疗期间无不良反应,对照组出现频发室性早搏4例,短阵室速1例,减低剂量后缓解。结论与多巴酚丁胺比较,心脉隆注射液治疗老年慢性心力衰竭合并缓慢心律失常,能显著缓解患者临床症状,改善心、肾功能,控制心律失常,安全有效,值得临床推广。
Objective To investigate the clinical effect of Xinmailong Injection for treating elderly patients with chronic heart failure complicated with slow arrhythmia and its effect on SCr,BUN and NT-proBNP.Methods Totally 112 elderly patients with chronic heart failure complicated with slow arrhythmia admitted to our hospital from January 2014 to January 2017 were randomly divided into the control group and the observation group,56 cases in each group.The two groups were given the basic treatment of the primary disease and routine treatment,the observation group was given intravenous infusion of Xinmailong Injection,the control group was maintained by intravenous infusion of dobutamine,and the two groups were treated for 10 d.Results The total effective rate of the observation group was 92.8 6%,which was significantly higher than 64.29%of the control group(<0.05).After treatment,the levels of NT-proBNP,SCr and BUN in the observation group were significantly lower than those before treatment and those in the control group(P<0.05).The LVEF,heart rate and 24 h urine volume of the observation group were significantly higher than those before treatment and those in the control group(P<0.05).There was no adverse reaction in the observation group during the treatment,but there were 4 cases of frequent ventricular premature beat(FVPB)and 1 case of non-sustained ventricular tachycardia(NSVT)in the control group,the symptoms were relieved after reducing the dose.Conclusion Compared with dobutamine,Xinmailong Injection for treating elderly patients with chronic heart failure complicated with slow arrhythmia can significantly relieve clinical symptoms,improve heart and kidney function and control arrhythmia.It is safe and effective,which is worthy of clinical promotion.
作者
韩尊
刘艳丽
Han Zun;Liu Yanli(Department of Cardiology,The First Hospital of Handan,Handan,Hebei,China056002)
出处
《中国药业》
CAS
2018年第5期55-57,共3页
China Pharmaceuticals
